Unit:
Τομέας ΠαθολογίαςLibrary of the School of Health Sciences
Author:
Gardikas Nikolaos
Dissertation committee:
Κωνσταντόπουλος Κωνσταντίνος, Καθηγητής, Ιατρική, ΕΚΠΑ
Παππά Βασιλική, Αναπληρώτρια Καθηγήτρια, Ιατρική, ΕΚΠΑ (Επιβλέπουσα)
Κοντοπίδου Φλώρα, Αναπληρώτρια Καθηγήτρια, Ιατρική, ΕΚΠΑ
Βασιλακόπουλος Θεόδωρος του Παναγιώτη, Αναπληρωτής Καθηγητής, Ιατρική, ΕΚΠΑ
Αγγελοπούλου Μαρία, Αναπληρώτρια Καθηγήτρια, Ιατρική, ΕΚΠΑ
Καψιμάλη-Βαϊοπούλου Βιολέττα, Αναπληρώτρια Καθηγήτρια, Ιατρική, ΕΚΠΑ
Βύνιου Αθηνά, Αναπληρώτρια Καθηγήτρια, Ιατρική, ΕΚΠΑ
Original Title:
Ανοσοφαινοτυπική και λειτουργική μελέτη αρχέγονων αιμοποιητικών κυττάρων στο μυελό των οστών ασθενών με πρωτοπαθές μυελοδυσπλαστικό σύνδρομο
Translated title:
Immunophenotypic and functional study of primary hematopoietic cells in the bone marrow of patients with primary myelodysplastic syndrome
Summary:
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell
disorders with unknown etiology. Multiparameter flow cytometry (MFC) is being
evaluated for the diagnosis and prognosis of MDS.
In the present study five-color MFC was performed on bone marrow
aspirates of 50 untreated patients, newly diagnosed with MDS and 27 age
matched control samples. Patients were classified according to World Health
Organization 2008 (WHO), International Prognostic Scoring System (IPSS) and
Revised IPSS (IPSS-R).
Significantly higher CD133+/CD90-CD45weak, CD117+/TdTCD45weak
and CD33+/MPO- Neutrophil Precursor (NP) percentages on
CD34+ cells, as well as a significant decrease of lymphoid and erythroid
precursors was observed in the group of MDS patients in comparison to
controls. A new scoring system was based on these findings which can be
helpful in lower-risk MDS patients’ discrimination, including those with normal
karyotype (a subgroup of MDS with diagnostic challenges). In addition, an
increased level of apoptosis of CD34+/CD117+ cells was identified as an
independent favorable prognostic factor both for the risk of transformation to
AML and for overall survival.
A new scoring system based on the expression of immature cell antigens
on CD34+ cells (by itself or in combination with the Ogata score) can
discriminate lower-risk MDS patients, including those with normal karyotype,
from the normal control group.
Main subject category:
Health Sciences
Keywords:
Myelodysplastic syndromes, CD34+ subpopulations, Immunophenotype, Diagnosis, Prognosis, Apoptosis
Number of references:
148
File:
File access is restricted only to the intranet of UoA.
Gardikas Nikolaos PhD.pdf
4 MB
File access is restricted only to the intranet of UoA.
